

## Agenda

2:00 - 2:30	<b>Registrations   Coffee and Tea</b>
2:30 - 2:40	<b>Welcome &amp; Introduction</b> <i>Andreas Kocourek, Head of Sales Region ANZ, Sartorius</i>
2:40 - 3:00	<b>Setting the Standard in Cell and Gene Therapy, Together</b> This presentation will offer a high-level overview of the current trends for Cell & Gene Therapies, focusing on key industry challenges and customer needs. We will highlight how, as a leading solution provider, we are setting the standard in this evolving field, working together to drive innovation and ensure the successful delivery of transformative therapies. <i>Cheng Qingling, Platform Development Specialist BPS Sales APAC, Sartorius</i>
3:00 - 3:30	<b>Get a Headstart: Advancing Scalable Cell and Gene Therapies with Quality-Driven Media and Reagents</b> <i>Mayank Gupta, Product Specialist CMTS CCM, Product Excellence CMTS APAC, Sartorius</i>
3:30 - 3:45	<b>Linkit® AX – Your Smart Simultaneous Aliquoting Solutions</b> The Linkit® AX solution was expertly designed to overcome the challenges of manual filling and aliquoting, without requiring investment in complex equipment. This advanced aseptic filling system efficiently channels process fluids into 10 Flexsafe® bags, enabling rapid and simultaneous filling. Its plug-and-play design, enhanced by a patented, ready-to-use bag distribution manifold, significantly reduces operator effort and error, ensuring precise fluid distribution into each of the 10 bags with an impressive accuracy of ±5.1% (applicable for 250mL, 500mL, and 1000mL bags). This makes it an ideal solution for aliquoting small fluid quantities in applications such as small-batch media preparation for cell and gene therapy, as well as other process fluid aliquoting tasks. <i>Clinton Simpson, Product Specialist, Product Excellence FMT APAC, Sartorius</i>
3:45 - 4:00	<b>Aseptic Cell Harvest &amp; Concentration in Cell Therapy Manufacturing</b> An automated, single-use solution designed to minimize contamination risks by reducing the need for manual handling. Ksep offers scalable counterflow continuous processing for aseptic cell concentration, wash, and harvest in cell therapy manufacturing, supporting high recoveries. By harmonizing a balance between centrifugal and fluid flow forces, it imparts very low shear on cells, ensuring high viability and yield. The automated cell wash feature enhances harvest quality in cell processing applications. The Ksep® system is adaptable from process development (0.1 L) to commercial manufacturing (200 L), providing seamless scalability. <i>Amit Khanna, Manager of Product Excellence ST APAC, Sartorius</i>
4:00 - 4:15	<b>Break</b>
4:15 - 4:45	<b>Innovation at its Best: Optimizing Upstream and Downstream Lentivirus Manufacturing Processes for CAR-T Cell Generation</b> While several CAR-T cell therapies are already approved, patient access remains a fundamental challenge. How can manufacturing innovation enable better upstream yields and downstream recovery to reduce cost per dose? In this session we explore innovation at its best to improve plasmid engineering, transient lentivirus production as well as lentiviral purification performance with newly developed chemical modifications for functional CAR-T cell generation. <i>Blaz Bakalar, Product Manager, Sartorius</i>
4:45 - 5:00	<b>Rapid &amp; Automated Direct Quantification of Total Virus Particles</b> A robust analytical tool delivering virus counts in near real-time. This system is adaptable across various virus growth and purification processes, offering versatility across numerous applications. Pinpoint optimal harvesting periods, validate processing stages, and establish final formulations efficiently and confidently. Viruses are labeled using specific reagents, employing either a direct dye method or high-affinity monoclonal antibodies. Subsequently, samples undergo precise and intense laser illumination. This method facilitates swift, direct, and precise quantification of total virus particles within a sample. <i>Amit Khanna, Manager of Product Excellence ST APAC, Sartorius</i>
5:00 - 5:15	<b>CAR-T Characterization: Leveraging Live-Cell Analysis and HTS Cytometry</b> "The development of gene modified cell therapies, in particular chimeric antigen receptor (CAR) T-cell therapy, has revolutionized cancer treatment by enabling personalized intelligent medicine, with the potential to cure disease. Owing to the success of CAR T-cell therapy, research in this field has boomed. Still, there are many limitations such as toxicity, limited efficacy against solid tumors, antigen escape, poor trafficking, and tumor infiltration that require to be addressed. In order to overcome these significant challenges, innovative strategies and approaches to engineer more powerful CAR-T cells are necessary. In this talk, we will consider how by leveraging Incucyte®'s live-cell analysis and iQue®'s high-throughput screener by cytometry platforms, researchers can be better equipped at assessing the criteria for developing and advancing future gene modified cell therapies." <i>Nabiha Elias, Ph.D., BioA Field Application Specialist, APAC, Sartorius</i>
5:15 - 5:20	<b>Q&amp;A and Closing Notes</b> <i>Andreas Kocourek, Head of Sales Region ANZ, Sartorius</i>
5:20 onwards	<b>Networking</b>

## Speakers

						
<b>Andreas Kocourek</b> Head of Sales Region ANZ, Sartorius	<b>Cheng Qingling</b> Platform Development Specialist BPS Sales APAC, Sartorius	<b>Mayank Gupta</b> Product Specialist CMTS CCM, Product Excellence CMTS APAC, Sartorius	<b>Clinton Simpson</b> Product Specialist, Product Excellence FMT APAC, Sartorius	<b>Amit Khanna</b> Manager of Product Excellence ST APAC, Sartorius	<b>Blaz Bakalar</b> Product Manager, Sartorius	<b>Nabiha Elias, Ph.D.</b> BioA Field Application Specialist, APAC, Sartorius